Exploring the determinants that influence hospital costs of induction therapy for acute myeloid leukemia

References

• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606.
   PubMed Web of Science ®Google Scholar
• Shah A, Andersson TM, Rachet B, et al. Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. Br J Haematol. 2013;162(4):509–516.
   PubMed Web of Science ®Google Scholar
• Bower H, Andersson TM, Bjorkholm M, et al. Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life. Blood Cancer J. 2016;6(2):e390–e390.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Podoltsev NA, Stahl M, Zeidan AM, et al. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev. 2017;31(2):43–62.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014;32(24):2541–2552.
   PubMed Web of Science ®Google Scholar
• Pandya BJ, Chen CC, Medeiros BC, et al. Economic and clinical burden of relapsed and/or refractory active treatment episodes in patients with acute myeloid leukemia (AML) in the USA: a retrospective analysis of a commercial payer database. Adv Ther. 2019;36(8):1922–1935.
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Shallis RM, Wang R, et al. Healthcare expenses for treatment of acute myeloid leukemia. Expert Rev Hematol. 2019;12(8):641–650.
   PubMed Web of Science ®Google Scholar
• Yi M, Li A, Zhou L, et al. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13(1):72.
   PubMed Web of Science ®Google Scholar
• Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeloid leukemia in Sweden. Int J Technol Assess Health Care. 1994;10(4):683–694.
   PubMedGoogle Scholar
• Clavio M, Quintino S, Masoudi B, et al. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. J Exp Clin Cancer Res. 2001;20(2):165–173.
   PubMed Web of Science ®Google Scholar
• Leunis A, Blommestein HM, Huijgens PC, et al. The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leuk Res. 2013;37(3):245–250.
   PubMed Web of Science ®Google Scholar
• Nerich V, Lioure B, Rave M, et al. Induction-related cost of patients with acute myeloid leukaemia in France. Int J Clin Pharm. 2011;33(2):191–199.
   PubMed Web of Science ®Google Scholar
• El-Zawahry HM, Zeeneldin AA, Samra MA, et al. Cost and outcome of treatment of adults with acute myeloid leukemia at the National Cancer Institute-Egypt. J Egypt Natl Canc Inst. 2007;19(2):106–113.
   PubMedGoogle Scholar
• Sun Q, Santoro MA, Meng Q, et al. Pharmaceutical policy in China. Health Aff (Millwood). 2008;27(4):1042–1050.
   PubMed Web of Science ®Google Scholar
• Zhang H, Hu H, Wu C, et al. Impact of China’s public hospital reform on healthcare expenditures and utilization: a case study in ZJ Province. PLoS One. 2015;10(11):e0143130.
   PubMed Web of Science ®Google Scholar
• Zhu D, Shi X, Nicholas S, et al. Impact of China’s healthcare price reforms on traditional Chinese medicine public hospitals in Beijing: an interrupted time-series study. BMJ Open. 2019;9(8):e029646.
   PubMed Web of Science ®Google Scholar
• Stein EM, Bonifacio G, Latremouille-Viau D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations. J Med Econ. 2018;21(6):556–563.
   PubMed Web of Science ®Google Scholar
• Bosshard R, O’Reilly K, Ralston S, et al. Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia. Cancer Treat Rev. 2018;69:224–232.
   PubMed Web of Science ®Google Scholar
• Redaelli A, Botteman MF, Stephens JM, et al. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev. 2004;30(3):237–247.
   PubMed Web of Science ®Google Scholar
• Vaughn JE, Buckley SA, Walter RB. Outpatient care of patients with acute myeloid leukemia: benefits, barriers, and future considerations. Leuk Res. 2016;45:53–58.
   PubMed Web of Science ®Google Scholar
• Vaughn JE, Othus M, Powell MA, et al. Resource utilization and safety of outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia or myelodysplastic syndrome: a nonrandomized clinical comparative analysis. JAMA Oncol. 2015;1(8):1120–1127.
   PubMed Web of Science ®Google Scholar
• Halpern AB, Walter RB, Estey EH. Outpatient induction and consolidation care strategies in acute myeloid leukemia. Curr Opin Hematol. 2019;26(2):65–70.
   PubMed Web of Science ®Google Scholar
• Allan DS, Buckstein R, Imrie KR. Outpatient supportive care following chemotherapy for acute myeloblastic leukemia. Leuk Lymphoma. 2001;42(3):339–346.
   PubMed Web of Science ®Google Scholar
• Cannas G, Fattoum J, Boukhit M, et al. Economic analysis of blood product transfusions according to the treatment of acute myeloid leukemia in the elderly. Transfus Clin Biol. 2015;22(5–6):341–347.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Mahmoud D, Kucmin-Bemelmans IT, et al. Economic burden associated with acute myeloid leukemia treatment. Expert Rev Hematol. 2016;9(1):79–89.
   PubMed Web of Science ®Google Scholar
• Batty N, Yin Y, Wetzler M. Decitabine is more cost effective than cytarabine and daunorubicin in elderly acute myeloid leukemia patients. J Cancer Res Ther. 2014;2(4):68–73.
   Google Scholar